Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency

Trial Profile

PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints): A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Efficacy and Safety of Pegzilarginase in Children and Adults With Arginase 1 Deficiency

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegzilarginase (Primary)
  • Indications Hyperargininaemia
  • Focus Pharmacokinetics; Registrational
  • Acronyms PEACE
  • Sponsors Aeglea Biotherapeutics
  • Most Recent Events

    • 29 Aug 2019 According to an Aeglea Biotherapeutics media release, trial design data will be presented as an e-poster at the 2019 Symposium of the Society for the Study of Inborn Errors of Metabolism (SSIEM) (in Rotterdam, the Netherlands, 6th Sep 2019).
    • 03 Jun 2019 According to an Aeglea Bio Therapeutics media release, first patient has been dosed.
    • 16 Apr 2019 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top